Market research
XBIO Xenetic Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 40
- Dividend yield
- Not available
- Beta
- 2.15
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US9840156023
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 40
- Dividend yield
- Not available
- Beta
- 2.15
About
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XBIO discussion.
5 years, 4 months ago
Xenetic Biosciences, Inc is currently in a long term downtrend where the price is trading 4.4% below its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.9.
Xenetic Biosciences, Inc's total revenue rose by 786.7% to $151K since the same quarter in the previous year.
Its net income has dropped by 2.5% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.2% to $-954K since the same quarter in the previous year.
Based on the above factors, Xenetic Biosciences, Inc gets an overall score of 3/5.